Circulation · 2004 · 252 citations · 38 references
Life SciencesImmunologyInternal MedicineAutoimmunityInflammationRheumatologyAutoimmune DiseasesAutoimmune InflammationAutoimmune Rheumatic DiseasesInflammatory ArthritisRheumatoid ArthritisVascular PathologyAtherosclerotic Plaque CharacterizationAtherosclerotic Plaque RuptureAtherosclerotic ProgressionCarotid Artery AtherosclerosisCd28 SignalingCd4 Positive T CellsFlow-mediated VasodilationVascular Endothelial Dysfunction
BACKGROUND: Peripheral blood expansion of an unusual CD4+ T-cell subset lacking surface CD28 has been suggested to predispose rheumatoid arthritis (RA) patients to develop more aggressive disease. However, the potential association between CD4+CD28null T cells and early atherosclerotic changes in RA has never been investigated. METHODS AND RESULTS: The number of circulating CD4+CD28null cells was evaluated in 87 RA and 33 control subjects who also underwent evaluation of carotid artery intima-media thickness (IMT) and endothelial function via flow-mediated vasodilation (FMV). Patients had higher IMT and lower FMV compared with control subjects. The frequency of CD4+CD28null cells was significantly higher in patients than in control subjects. Twenty patients with persistent expansion of circulating CD4+CD28null cells had more marked increase of carotid artery IMT and stronger decrease of brachial artery FMV. Blockade of tumor necrosis factor-alpha led to a partial reappearance of the CD28 molecule on the CD4+ cell surface. CONCLUSIONS: Circulating CD4+CD28(null) lymphocytes are increased in RA. Patients with persistent CD4+CD28null cell expansion show preclinical atherosclerotic changes, including arterial endothelial dysfunction and carotid artery wall thickening, more significantly than patients without expansion. These findings suggest a contribution of this cell subset in atheroma development in RA. Moreover, the demonstration that tumor necrosis factor-alpha blockade is able to reverse, at least in part, the CD28 deficiency on the CD4+ cell surface may be of interest for possible innovative therapeutic strategies in cardiovascular diseases.
38
M.L.L. Prevoo, Martin A. van't Hof, H. H. Kuper et al. · Arthritis & Rheumatism · 1995 · 6.2K citations
Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis
Daniel H. Solomon, Elizabeth W. Karlson, Eric B. Rimm et al. · Circulation · 2003 · 1.3K citations · Full text